

National Rice Advisory Committee at 1 pm on November 28, 1972, and at 9 am on November 29, 1972, in Room 218-A of the Administration Building, U.S. Department of Agriculture, Washington, D.C. The purpose of this meeting is to discuss the supply and demand situation for the 1972 rice crop and the requirements for the 1973 rice crop. The meeting will be open to the public.

The names of Committee members, agenda, summary of the meeting, and other information pertaining to the meeting may be obtained from Harlan H. Holleman, Director, Oilseeds and Special Crops Division, ASCS, South Building, Room 5768, Washington, D.C. Telephone: 202-44-77973.

GLENN A. WEIR,
Acting Administrator, Agricultural Stabilization and Conservation Service.

NOVEMBER 22, 1972.

[FR Doc.72-20491 Filed 11-27-72;8:54 am]

DEPARTMENT OF COMMERCE

Maritime Administration

[Docket No. S-313]

ACADEMY TANKERS, INC., ET AL.

Notice of Multiple Applications

Notice is hereby given that the following corporations have filed application for an operating-differential subsidy contract to carry bulk cargoes to expire on June 30, 1973 (unless extended only for subsidized voyages in progress on that date). The bulk cargo carrying vessels proposed to be subsidized and the trades in which each proposes to engage are presented also.

Applicant's name and address	Type of ship	Name of ship
Academy Tankers, Inc., Americana Bldg., 811 Dallas Ave., Houston, TX 77002.	Tanker....	SS Thomas A. Thomas Q.
Marine Carriers Corp., 17 Battery Pl., New York, NY 10004.	Bulk carrier.	SS Commander.
American Trading Transportation Company, Inc., 555 8th Ave., New York, NY 10017.	Tanker....	SS Maryland Trader. SS Virginia Trader. SS Washington Trader.
Penn Tanker Co., 405 Park Ave., New York, NY 10022.do.....	SS Penn Champion. SS Penn Challenger.
Mount Vernon Tanker Co., 888 7th Ave., New York, NY 10019.do.....	SS Mount Victory. SS Mount Washington.
World Wide Tankers, Inc., 1 New York Plaza, New York, NY 10004.do.....	SS Barbara Jane.
Vancor Steamship Corp., 11 Broadway, New York, NY 10004.do.....	SS Vantage Horizon.

The foregoing applications may be inspected in the Office of the Secretary, Maritime Subsidy Board, Maritime Administration, U.S. Department of Com-

merce, Washington, D.C. during regular working hours.

These vessels are to engage in the carriage of export bulk raw and processed agricultural commodities in the foreign commerce of the United States (U.S.) from ports in the U.S. to ports in the Union of Soviet Socialist Republics (U.S.S.R.), or other permissible ports of discharge. Liquid and dry bulk cargoes may be carried from U.S.S.R. and other foreign ports inbound to U.S. ports during voyages subsidized for carriage of export bulk raw and processed agricultural commodities to the U.S.S.R.

Full details concerning the U.S.-U.S.S.R. export bulk raw and processed agricultural commodities subsidy program, including terms, conditions, and restrictions upon both the subsidized operators and vessels, appear in the regulations published in the FEDERAL REGISTER on November 16, 1972 (37 F.R. 24349).

For purposes of section 605(c), Merchant Marine Act, 1936, as amended (Act), it should be assumed that each vessel named will engage in the trades described on a full-time basis through June 30, 1973 (with extension to termination of approved subsidized voyages in progress on that date). Each voyage must be approved for subsidy before commencement of the voyage. The Maritime Subsidy Board (Board) will act on each request for a subsidized voyage as an administrative matter under the terms of the individual operating-differential subsidy contract for which there is no requirement for further notices under section 605(c) of the Act.

Any person having an interest in the granting of one or any of such applications and who would contest a finding of the Board that the service now provided by vessels of U.S. registry for the carriage of cargoes as previously specified is inadequate, must, on or before December 4, 1972, notify the Board's Secretary, in writing, of his interest and of his position, and file a petition for leave to intervene in accordance with the Board's rules of practice and procedure (46 CFR Part 201). Each such statement of interest and petition to intervene shall state whether a hearing is requested under section 605(c) of the Act and with as much specificity as possible the facts that the intervenor would undertake to prove at such hearing. Further, each such statement shall identify the applicant or applicants against which the intervention is lodged.

In the event a hearing under section 605(c) of the Act is ordered to be held with respect to any application(s), the purpose of such hearing will be to receive evidence relevant to (1) whether the application(s) hereinabove described is one with respect to vessels to be operated in an essential service, served by citizens of the United States which would be in addition to the existing service, or services, and if so, whether the service already provided by vessels of U.S. registry is inadequate, and (2) whether in the accomplishment of the purposes and policy of the Act additional vessels should be operated thereon.

If no request for hearing and petition for leave to intervene is received within the specified time, or if the Board determines that petitions for leave to intervene filed within the specified time do not demonstrate sufficient interest to warrant a hearing, the Board will take such action as may be deemed appropriate.

Dated: November 22, 1972.

By order of the Maritime Subsidy Board.

JAMES S. DAWSON, Jr.,
Secretary.

[FR Doc.72-20447 Filed 11-27-72;8:51 am]

CONSTRUCTION OF LIQUEFIED NATURAL GAS (LNG) VESSELS WITH CONCH SELF-SUPPORTING TANK DESIGN

Notice of Intent To Compute Estimated Foreign Cost

Notice is hereby given of the intent of the Maritime Subsidy Board, pursuant to the provisions of section 502(b) of the Merchant Marine Act, 1936, as amended, to compute the estimated foreign cost of the construction of 125,000 cubic meter liquefied natural gas (LNG) vessels with Conch self-supporting tank design.

Any person, firm, or corporation having any interest (within the meaning of section 502(b)) in such computations may file written statements by the close of business on December 8, 1972, with the Secretary, Maritime Subsidy Board, Maritime Administration, Room 3099B, Department of Commerce Building, 14th and E Streets NW., Washington, DC 20235.

Dated: November 24, 1972.

By order of the Maritime Subsidy Board, Maritime Administration.

JAMES S. DAWSON, Jr.,
Secretary.

[FR Doc.72-20512 Filed 11-27-72;8:55 am]

DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE

Food and Drug Administration

[DESI 10971; Docket No. FDC-D-561; NDA 10-971 etc.]

AYERST LABORATORIES AND WALLACE LABORATORIES

Conjugated Estrogens With Meprobamate; Notice of Opportunity for Hearing on Proposal To Withdraw Approval of New Drug Applications

In an announcement (DESI 10971) published in the FEDERAL REGISTER of August 26, 1970 (35 F.R. 13607), the Commissioner of Food and Drugs an-

nounced his conclusions pursuant to the evaluation of two reports received from the National Academy of Sciences-National Research Council, Drug Efficacy Study Group, on the following drugs containing conjugated estrogens with meproamate:

NDA 10-971; PMB-200 and PMB-400 tablets, marketed by Ayerst Laboratories, Division of American Home Products Corporation, 685 Third Avenue, New York, N.Y. 10017.

NDA 11-045; Milprem-200 and Milprem-400 tablets, marketed by Wallace Laboratories, Division of Carter-Wallace Inc., Half Acre Road, Cranbury, N.J. 08512.

The announcement stated that the Food and Drug Administration has considered the Academy reports, as well as other available evidence, and concludes there is a lack of substantial evidence that such fixed combination drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the labeling and that each component of the combination drug contributes to the total effects claimed, and that the Commissioner of Food and Drugs intended to initiate proceedings to withdraw approval of the new drug applications. Interested persons were invited to submit pertinent data bearing on the proposal within 30 days following publication of the announcements. No data providing substantial evidence of effectiveness were received pursuant to the announcement.

Therefore, notice is given to the holder(s) of the new drug application(s) and to any other interested person that the Commissioner proposes to issue an order under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) withdrawing approval of the listed new drug application(s) and all amendments and supplements thereto on the grounds that new information before him with respect to the drug(s), evaluated together with the evidence available to him at the time of approval of the application(s), shows there is a lack of substantial evidence that the drug(s) will have all the effects purported or represented to have under the conditions of use prescribed, recommended, or suggested in the labeling.

All identical, related, or similar products, not the subject of an approved new drug application, are covered by the new drug application(s) reviewed. See 21 CFR 130.40 (37 F.R. 23185, October 31, 1972). Any manufacturer or distributor of such an identical, related, or similar product is an interested person who may in response to this notice submit data and information, request that the new drug application(s) not be withdrawn, request a hearing, and participate as a party in any hearing. Any person who wishes to determine whether a specific product is covered by this notice should write to the Food and Drug Administration, Bureau of Drugs, Office of Compliance (BD-300), 5600 Fishers Lane, Rockville, Md. 20852.

In accordance with the provisions of section 505 of the Act (21 U.S.C. 355) and the regulations promulgated thereunder (21 CFR Part 130), the Commissioner hereby gives the applicant(s) and any other interested person an opportunity for a hearing to show why approval of the new drug application(s) should not be withdrawn.

Within 30 days after publication hereof in the FEDERAL REGISTER the applicant(s) and any other interested person is required to file with the Hearing Clerk, Department of Health, Education, and Welfare, Room 6-88, 5600 Fishers Lane, Rockville, Md. 20852, a written appearance electing whether or not to avail himself of the opportunity for a hearing. Failure of an applicant or any other interested person to file a written appearance of election within said 30 days will constitute an election by him not to avail himself of the opportunity for a hearing.

If no person elects to avail himself of the opportunity for a hearing, the Commissioner without further notice will enter a final order withdrawing approval of the application(s).

If an applicant or any other interested person elects to avail himself of the opportunity for a hearing, he must file, within 30 days after publication of this notice in the FEDERAL REGISTER, a written appearance requesting the hearing, giving the reasons why approval of the new drug application(s) should not be withdrawn, together with a well-organized and full-factual analysis of the clinical and other investigational data he is prepared to prove in support of his opposition. A request for a hearing may not rest upon mere allegations or denials, but must set forth specific facts showing that a genuine and substantial issue of fact requires a hearing (21 CFR 130.14(b)).

If review of the data submitted by an applicant or any other interested person warrants the conclusion that there exists substantial evidence demonstrating the effectiveness of the product(s) for the labeling claims involved, the Commissioner will rescind this notice of opportunity for hearing.

If review of the data in the application(s) and data submitted by the applicant(s) or any other interested person in a request for a hearing, together with the reasoning and factual analysis in a request for a hearing, warrants the conclusion that no genuine and substantial issue of fact precludes the withdrawal of approval of the application(s), the Commissioner will enter an order of withdrawal making findings and conclusions on such data.

If, upon the request of the new drug applicant(s) or any other interested person, a hearing is justified, the issues will be defined, a hearing examiner will be named, and he shall issue, as soon as practicable after the expiration of such 30 days, a written notice of the time and place at which the hearing will commence. All persons interested in identical, related, or similar products covered by the new drug application(s) will be afforded an opportunity to appear at the

hearing, file briefs, present evidence, cross-examine witnesses, submit suggested findings of fact, and otherwise participate as a party. The hearing contemplated by this notice will be open to the public except that any portion of the hearing that concerns a method or process the Commissioner finds entitled to protection as a trade secret will not be open to the public, unless the respondent specifies otherwise in his appearance.

Requests for a hearing and/elections not to request a hearing may be seen in the Office of the Hearing Clerk (address given above) during regular business hours, Monday through Friday.

This notice is issued pursuant to provisions of the Federal Food, Drug, and Cosmetic Act (sec. 505, 52 Stat. 1052-53, as amended; 21 U.S.C. 355), and the Administrative Procedure Act (5 U.S.C. 554), and under authority delegated to the Commissioner (21 CFR 2.120).

Dated: November 14, 1972.

SAM D. FINE,
Associate Commissioner
for Compliance.

[FR Doc.72-20345 Filed 11-27-72; 8:47 am]

[DESI 9414; Docket No. FDC-D-528; NDA 9-414 etc.]

CERTAIN STEROID COMBINATION PREPARATIONS FOR ORAL USE

Notice of Opportunity for Hearing on Proposal To Withdraw Approval of New Drug Applications

In an announcement (DESI 9414) published in the FEDERAL REGISTER of July 11, 1972 (37 F.R. 13566), the Commissioner of Food and Drugs announced his conclusions pursuant to the evaluation of reports received from the National Academy of Sciences-National Research Council, Drug Efficacy Study Group, on the following drugs:

A. PREDNISONE IN COMBINATION WITH OTHER ACTIVE COMPONENTS

1. Co-Deltra Tablets containing 2.5 mg. or 5.0 mg. prednisone, magnesium trisilicate, and dried aluminum hydroxide gel; Merck Sharp & Dohme, Division Merck and Co., Inc., West Point, Pa. 19486 (NDA 10-371).

B. PREDNISOLONE IN COMBINATION WITH OTHER ACTIVE COMPONENTS

1. Ataraxoid Tablets containing 2.5 mg. or 5.0 mg. prednisolone and hydroxyzine hydrochloride; Chas. Pfizer and Co., Inc., 235 East 42d Street, New York, NY 10017 (NDA 10-636).

2. Cordex Tablets and Cordex-Forte Tablets containing prednisolone and aspirin (NDA 10-185); and

3. Cordex (Buffered) Tablets and Cordex-Forte (Buffered) Tablets containing prednisolone, aspirin, and calcium carbonate (NDA 10-185); The Upjohn Co., 7171 Portage Road, Kalamazoo, MI 49002.

4. Deltacortril-APC Tablets containing prednisolone, aspirin, phenacetin,